¼±Åà - È­»ìǥŰ/¿£ÅÍŰ ´Ý±â - ESC

 
"Factor X activated"¿¡ ´ëÇÑ °Ë»ö °á°úÀÔ´Ï´Ù. °Ë»ö °á°ú º¸´Â µµÁß¿¡ Tab ۸¦ ´©¸£½Ã¸é °Ë»ö âÀÌ ¼±Åõ˴ϴÙ.
´ëÇÑÀÇÇù ÀÇÇпë¾î »çÀü °Ë»ö À¯»ç °Ë»ö °á°ú : 15 ÆäÀÌÁö: 8
  • ¿µ¹®
    ÇѱÛ
  • oxygen gain factor
    »ê¼ÒÀ̵æ°è¼ö
  • plasma coagulation factor
    Ç÷ÀåÀÀ°íÀÎÀÚ
  • plasma thromboplastin factor
    Ç÷À寮·Òº¸ÇÃ¶ó½ºÆ¾ÀÎÀÚ
  • platelet activating factor
    Ç÷¼ÒÆÇȰ¼ºÀÎÀÚ
  • platelet factor 3
    Ç÷¼ÒÆÇÀÎÀÚ3
  • platelet factor 4
    Ç÷¼ÒÆÇÀÎÀÚ4
  • platelet-derived growth factor
    Ç÷¼ÒÆÇÀ¯·¡¼ºÀåÀÎÀÚ, Ç÷¼ÒÆÇ±â¿ø¼ºÀåÀÎÀÚ
  • precipitation factor
    ħÀüÀÎÀÚ
  • predisposing factor
    ¼±Çà¿äÀÎ
  • prognostic factor
    ¿¹ÈÄÀÎÀÚ
  • prolactin inhibitory factor
    ÇÁ·Î¶ôƾºÐºñ¾ïÁ¦ÀÎÀÚ
  • prolactin releasing factor
    ÇÁ·Î¶ôƾºÐºñÀÎÀÚ
  • properdin factor B
    ÇÁ·ÎÆä¸£µòBÀÎÀÚ
  • properdin factor D
    ÇÁ·ÎÆä¸£µòDÀÎÀÚ
  • properdin factor E
    ÇÁ·ÎÆä¸£µòEÀÎÀÚ
¿¾ ´ëÇÑÀÇÇù ÀÇÇпë¾î »çÀü °Ë»ö À¯»ç °Ë»ö °á°ú : 15 ÆäÀÌÁö: 8
  • ¿µ¹®
    ÇѱÛ
  • psychological factor
    ½É¸®¿ä¼Ò
  • psychosocial factor
    ½É¸®»çȸÀû¿äÀÎ
  • quality factor
    Áú¿ä¼Ò, Á¤¼ºÀÎÀÚ
  • racial factor
    ÀÎÁ¾¿äÀÎ
  • radiation weighting factor
    ¹æ»ç¼±°¡Áß°è¼ö
  • realization factor
    ½ÇÇöÀÎÀÚ
  • recruitment factor
    µ¿¿øÀÎÀÚ
  • reducing factor
    ȯ¿øÀÎÀÚ
  • reinforcing factor
    °­È­¿äÀÎ
  • relaxing factor
    ÀÌ¿ÏÀÎÀÚ
  • resistance factor
    ³»¼ºÀÎÀÚ, °ßµõÀÎÀÚ
  • resistancetransfer factor
    ³»¼ºÀü´ÞÀÎÀÚ
  • reticuloendothelial depressant factor
    ¼¼¸Á³»Çǰè¾ïÁ¦ÀÎÀÚ, ±×¹°³»Çǰè¾ïÁ¦ÀÎÀÚ
  • rheumatoid factor
    ·ù¸¶Æ¼½ºÀ¯»çÀÎÀÚ
  • risk factor
    À§ÇèÀÎÀÚ
¿¾ ´ëÇÑÀÇÇù 2 ÀÇÇпë¾î »çÀü °Ë»ö À¯»ç °Ë»ö °á°ú : 15 ÆäÀÌÁö: 8
  • ¿µ¹®
    ÇѱÛ
  • growth factor
    ¼ºÀå ÀÎÀÚ(à÷íþ ì×í­)
  • growth factor, B cell (BCGF)
    B¼¼Æ÷ Áõ½ÄÃËÁøÀÎÀÚ
  • growth hormone-releasing factor
    ¼ºÀåÈ£¸£¸óÀ¯¸®ÀÎÀÚ<--¹æÃâÀÎÀÚ>
  • growth promoting factor
    ¼ºÀåÃËÁøÀÎÀÚ(à÷íþõµòäì×í­), ¹ßÀ°ÃËÁø¹°Áú(Û¡ëÀõµòäÚªòõ)
  • hageman factor
    ÇϰԸ¸ ÀÎÀÚ, Hageman ÀÎÀÚ
  • hematopoietic growth factor
    Á¶Ç÷¼ºÀåÀÎÀÚ
  • hemorrhagic diathesis,clotting factor abnormalities
    ÀÀ°íÀÎÀÚ ÀÌ»ó
  • hepatocyte growth factor
    °£¼¼Æ÷¼ºÀåÀÎÀÚ
  • histamine sensitizing factor =HSF
    È÷½ºÅ¸¹Î°¨ÀÛÀÎÀÚ(¡­ÊïíÂì×í­).
  • homologous restriction factor
    µ¿Á¾Á¦ÇÑÀÎÀÚ
  • hyperglycemic glycogenolytic factor
    °íÇ÷´ç¼º ´ç¿øºÐÇØ(¼º) ÀÎÀÚ.
  • hypothalamic releasing factor
    ½Ã»óÇϺÎÀ¯¸®ÀÎÀÚ(ë¤×ãì×í­).
  • hypothalamic releasing factor
    ½Ã»óÇϺιæÃâÀÎÀÚ.
  • hypothalamus releasing factor
    ½Ã»óÇϺÎÀ¯¸®ÀÎÀÚ.
  • inhibition(-tory) factor, macrophage migration
    ´ë½Ä¼¼Æ÷ À¯ÁÖÀúÁöÀÎÀÚ
¿¾ ´ëÇÑÀÇÇù 3 ÀÇÇпë¾î »çÀü °Ë»ö À¯»ç °Ë»ö °á°ú : 15 ÆäÀÌÁö: 8
  • ¿µ¹®
    ÇѱÛ
  • differentiation factor
    °¨º°¿äÀÎ, °¨º°¿ä¼Ò, °¨º°ÀÎÀÚ
  • dilution factor
    ¹±ÈûÀÎÀÚ(ÊÙËöËö), Èñ¼®ÀÎÀÚ.
  • dilution factor
    ¹±ÈûÀÎÀÚ(¡­ì×í­), Èñ¼®ÀÎÀÚ.
  • dose conversion factor
    ¼±·®º¯È¯°è¼ö
  • dose limiting factor
    ¼±·®ÇѵµÀÎÀÚ, ¼±·®Á¦ÇÑÀÎÀÚ
  • dose modifying factor
    ¼±·®¼ö½Ä°è¼ö
  • dose-reduction factor
    ¼±·®°¨¼Ò°è¼ö
  • drug resistance factor
    ¾àÁ¦³»¼ºÀÎÀÚ
  • drug resistance transfer factor
    ¾àÁ¦³»¼ºÀü´ÞÀÎÀÚ
  • duplicate factor
    Áߺ¹ÀÎÀÚ.
  • early pregnancy factor(EPF)
    ÃʱâÀÓ½ÅÀÎÀÚ
  • edaphic factor
    ÅäÁöÀÎÀÚ(ÊÙËöËö).
  • elongation factor
    ¿¬ÀåÀÎÀÚ(¡­ì×í­).
  • elongation factor
    ½ÅÀåÀÎÀÚ
  • enabling factor
    ÀÇ·áÀÌ¿ë °¡´É¿äÀÎ.
´ëÇÑ»ýÈ­ÇкÐÀÚ»ý¹°ÇÐȸ ¿ë¾î »çÀü °Ë»ö À¯»ç °Ë»ö °á°ú : 15 ÆäÀÌÁö: 8
  • ¿µ¹®
    ÇѱÛ
  • Lande G factor
    ¶õµ¥ G ÀÎÀÚ(ì×í­)
  • lard factor
    µ·Áö(ÔÊò·) ÀÎÀÚ(ì×í­)
  • leukocyte inhibitory factor
    ¹éÇ÷±¸ÀúÇØÀÎÀÚ(ÛÜúìϹîÁúªì×í­)
  • Lewis factor
    ·çÀ̽ºÀÎÀÚ(ì×í­)
  • lipoprotein tissue factor
    ÁöÁú´Ü¹éÁú(ò·òõÓ±ÛÜòõ) Á¶Á÷ÀÎÀÚ(ðÚòÄì×í­)
  • liver filtrate factor
    °£ ¿©°ú ÀÎÀÚ(ÊÜÕëΦì×í­)
  • LLD factor
    LLD ÀÎÀÚ(ì×í­)
  • L-L factor
    "L-L ÀÎÀÚ(ì×í­), (å²) Laki-Lorand ÀÎÀÚ(ì×í­)"
  • lymph node permeability factor
    ¸²ÇÁÀý(ï½)Åõ°úÀÎÀÚ(÷âΦì×í­)
  • lymphocyte-derived chemotactic factor
    ¸²ÇÁ±¸-À¯µµ(ë¯Óô) È­ÇÐÁÖ¼ºÀÎÀÚ(ûùùÊñËà÷ì×í­)
  • macrophage activation factor
    ´ë½Ä¼¼Æ÷Ȱ¼ºÀÎÀÚ(ÓÞãÝá¬øàüÀàõì×í­)
  • macrophage inhibition factor
    ´ë½Ä¼¼Æ÷ÀúÇØÀÎÀÚ(ÓÞãÝá¬øàîÁúªì×í­)
  • maize factor
    ¿Á¼ö¼ö ÀÎÀÚ(ì×í­)
  • maturation factor
    ¼º¼÷ÀÎÀÚ(à÷âÙì×í­)
  • migration enhancement factor
    À̵¿Ç×Áø ÀÎÀÚ(ì¹ÔÑùñòäì×í­)
KMLE ÀÇÇоà¾î »çÀü À¯»ç °Ë»ö °á°ú : 5 ÆäÀÌÁö: 8
ACAC acetyl-coenzyme A cocarboxylase; activated charcoal artificial cell
ACT achievement through counseling and treatment; actin; actinomycin; activated clotting time; advanced ...
A-LAK adherent lymphokine-activated killer [cell]
APC acetylsalicylic acid, phenacetin, and caffeine; activated protein C; adenoidal-pharyngeal-conjunctiv...
APTT, aPTT activated partial thromboplastin time
KMLE ÀÚµ¿ÃßÃâ ÀÇÇоà¾î »çÀü À¯»ç °Ë»ö °á°ú : 5 ÆäÀÌÁö: 8
JNK/SAPK Jun N-terminal kinase/stress activated protein kinase
LVA Low voltage-activated
LAK Lymphokine (IL-2)-activated-killer
LAK Lymphokine Activated Killer
LAK Lymphokine Activated Killing
°æºÏ´ë Ä¡°ú´ëÇÐ ±¸°­³»°ú ±³½Ç »çÀü À¯»ç °Ë»ö °á°ú : 15 ÆäÀÌÁö: 8
  • ¿µ¹®
    ÇѱÛ
    ¼³¸í
  • milk factor
    ¸ðÀ¯ ÀÎÀÚ
  • monocytosis-producing factor
    ´ÜÇÙ±¸ Áõ°¡Áõ À¯¹ß ÀÎÀÚ
  • multiple factor
    ´Ù¹ß¼º ÀÎÀÚ
  • myocardial depressant factor
    ½É±Ù ¾ïÁ¦ ÀÎÀÚ
  • natural moistening factor
    ÀÚ¿¬ º¸½À ÀÎÀÚ
  • negative cognitive factor
    ºÎÁ¤ÀûÀÎ ÀÎ½Ä ¿äÀεé
  • nutritional factor
    ¿µ¾ç ÀÎÀÚ
  • pathophysiologic factor
    º´Å »ý¸®ÇÐÀû ¿äÀÎ
  • pellagra preventive factor
    Æç¶ó±×¶ó ¿¹¹æ ÀÎÀÚ
  • platelet aggragating factor
    Ç÷¼ÒÆÇ ÀÀÁý ¿ä¼Ò, Ç÷¼ÒÆÇ ¾ÇÈ­ ÀÎÀÚ, Ç÷¼ÒÆÇ ¾ÇÈ­ ¿äÀÎ
    ¸é¿ª ±Û·ÎºÎ¸° E¿¡ °¨±¤µÈ È£¿°±â±¸¿¡¼­ÀÇ Ç׿ø ¹ÝÀÀ¿¡ ÀÇÇØ Ç÷¾× ³»¿¡ »ý¼ºµÈ ¹°Áú·Î¼­ Ç÷¼ÒÆÇÀ» ÀÀÁý½Ã۸ç, ¿°ÁõÀ» À¯¹ß½ÃŲ´Ù.
  • platelet-activating factor
    Ç÷¼ÒÆÇ Ȱ¼º ÀÎÀÚ
  • predisposing factor
    ¼ÒÀÎ, Áúº´ ¼ÒÁú
    ÁúȯÀ̳ª Àå¾Ö¸¦ À¯¹ß½Ãų À§Ç輺À» Áõ°¡½ÃŰ´Â ¿ä¼Ò.
  • psychogenic factor
    Á¤½ÅÀû ¿ä¼Ò, ½ÉÀμº ¿ä¼Ò
  • psychosocial factor
    »çȸ Á¤½ÅÀû ¿äÀÎ
  • quality factor
    Á¤¼º ÀÎÀÚ, Ư¼º ¿ä¼Ò, Áú ¿ä¼Ò
CancerWEB ¿µ¿µ ÀÇÇлçÀü À¯»ç °Ë»ö °á°ú : 15 ÆäÀÌÁö: 8
glass factor <chemical> Stable blood coagulation factor activated by contact with the subendothelial surface of an injured vessel. Along with prekallikrein, it serves as the contact factor that initiates the intrinsic pathway of blood coagulation. Kallikrein activates factor xii to xiia. Deficiency of factor xii, also called the hageman trait, leads to increased incidence of thromboembolic disease.
Chemical name: Blood-coagulation factor XII
(12 Dec 1998)
relaxation factor Substance presumably involved in the return of muscle fibrils to the resting state after nervous stimulation ceases, postulated to act by withdrawing Calcium from myosin-ATPase sites.
(05 Mar 2000)
release factor A component of the specialised transport system involved in the transport of cobalamin (vitamin B12) across the wall of the intestine. Dissociates the complex between cobalamin and the extracellular cobalamin binding glycoprotein known as intrinsic factor.
(18 Nov 1997)
vitamin B12 with intrinsic factor concentrate A combination of vitamin B12 with suitable preparations of the mucosa of the stomach or intestine of domestic animals used for food by humans.
(05 Mar 2000)
glucose tolerance factor A water-soluble complex containing chromium needed for normal glucose tolerance.
(05 Mar 2000)
resistance factor <molecular biology> A self-replicating fragment of nucleic acid that confers drug resistance and is transmitted from one bacterium to another via conjugation.
(09 Oct 1997)
resistance-inducing factor An agent from normal chick embryos that interferes with multiplication of the avian leukosis-sarcoma virus, and is seemingly an avirulent leukosis virus antigenically related to the avian leukosis-sarcoma virus.
(05 Mar 2000)
resistance-transfer factor The transfer gene of the resistance plasmid.
(05 Mar 2000)
pellagra-preventing factor A precursor of NAD, that is a product of the oxidation of nicotine.
(18 Nov 1997)
Von Willebrand factor Plasma factor involved in platelet adhesion through an interaction with Factor VIII.
See: Von Willebrand disease.
(18 Nov 1997)
von Willebrand factor-degrading protease <enzyme> A large protease from normal human plasma that degrades vwf at the 842tyr-843met peptide bond
Registry number: EC 3.4.24.-
Synonym: vwf-cleaving protease
(26 Jun 1999)
glycotropic factor A principle in extracts of the anterior lobe of the hypophysis that raises the blood sugar and antagonises the action of insulin; purified pituitary growth hormone produces an identical effect.
Synonym: insulin-antagonizing factor.
(05 Mar 2000)
melanotropin-releasing factor A hexapeptide similar to oxytocin; it stimulates the release of melanotropin.
Synonym: melanotropin-releasing factor, melanotropin-releasing hormone.
Origin: melanotropin + L. Libero, to free, + -in
(05 Mar 2000)
peptide elongation factor tu A protein found in bacteria and eukaryotic cells which delivers aminoacyl-trna's to the a site of the ribosome. The aminoacyl-trna is first bound to a complex of elongation factor tu containing a molecule of bound GTP. The resulting complex is then bound to the 70s initiation complex. Simultaneously the GTP is hydrolyzed and a tu-GDP complex is released from the 70s ribosome. The tu-GTP complex is regenerated from the tu-GDP complex by the ts elongation factor and GTP.
(12 Dec 1998)
gonadotropin-releasing factor <hormone> The peptide hormone that control reproductive function.
It produced and released by the hypothalamus and controls the production and release of gonadotrophins from the pituitary gland.
It causes the production of luteinising hormone and follicle-stimulating hormone.
Synonym: gonadotropin-releasing factor, gonadotropin-releasing hormone, luteinizing hormone/follicle-stimulating hormone-releasing factor, gonadoliberin.
Origin: Gonad + L. Libero, to free, + -in
(19 Sep 2002)
ÀÌ ¾Æ·¡ ºÎÅÍ´Â °á°ú°¡ ¾ø½À´Ï´Ù.
KMLE ¾àǰ/ÀǾàǰ ¸ÂÃã °Ë»ö °á°ú : 0 ÆäÀÌÁö: 8
  • Á¦Ç°¸í
    ¼ººÐ/ÇÔ·®
    ±¸ºÐ/º¸Çè±Þ¿©
KMLE ¾àǰ/ÀǾàǰ À¯»ç °Ë»ö °á°ú : 0 ÆäÀÌÁö: 8
  • Á¦Ç°¸í
    ¼ººÐ/ÇÔ·®
    ±¸ºÐ/º¸Çè±Þ¿©
¾Ë±â½¬¿î ÀÇÇпë¾îÇ®ÀÌÁý, ¼­¿ïÀÇ´ë ±³¼ö ÁöÁ¦±Ù, °í·ÁÀÇÇÐ ÃâÆÇ ¸ÂÃã °Ë»ö °á°ú : 0 ÆäÀÌÁö: 8
¾Ë±â½¬¿î ÀÇÇпë¾îÇ®ÀÌÁý, ¼­¿ïÀÇ´ë ±³¼ö ÁöÁ¦±Ù, °í·ÁÀÇÇÐ ÃâÆÇ À¯»ç °Ë»ö °á°ú : 0 ÆäÀÌÁö: 8
´ëÇÑÀÇÇù ÀÇÇпë¾î »çÀü °Ë»ö ¸ÂÃã °Ë»ö °á°ú : 0 ÆäÀÌÁö: 8
  • ¿µ¹®
    ÇѱÛ
´ëÇÑÀÇÇù Çʼö ÀÇÇпë¾îÁý »çÀü °Ë»ö ¸ÂÃã °Ë»ö °á°ú : 0 ÆäÀÌÁö: 8
  • ¿µ¹®
    ÇѱÛ
´ëÇÑÀÇÇù Çʼö ÀÇÇпë¾îÁý »çÀü °Ë»ö À¯»ç °Ë»ö °á°ú : 0 ÆäÀÌÁö: 8
  • ¿µ¹®
    ÇѱÛ
¿¾ ´ëÇÑÀÇÇù ÀÇÇпë¾î »çÀü °Ë»ö ¸ÂÃã °Ë»ö °á°ú : 0 ÆäÀÌÁö: 8
  • ¿µ¹®
    ÇѱÛ
¿¾ ´ëÇÑÀÇÇù 2 ÀÇÇпë¾î »çÀü °Ë»ö ¸ÂÃã °Ë»ö °á°ú : 0 ÆäÀÌÁö: 8
  • ¿µ¹®
    ÇѱÛ
¿¾ ´ëÇÑÀÇÇù 3 ÀÇÇпë¾î »çÀü °Ë»ö ¸ÂÃã °Ë»ö °á°ú : 0 ÆäÀÌÁö: 8
  • ¿µ¹®
    ÇѱÛ
´ëÇÑÇØºÎÇÐȸ ÀÇÇпë¾î »çÀü °Ë»ö ¸ÂÃã °Ë»ö °á°ú : 0 ÆäÀÌÁö: 8
  • ¿µ¹®
    ÇѱÛ
´ëÇÑÇØºÎÇÐȸ ÀÇÇпë¾î »çÀü °Ë»ö À¯»ç °Ë»ö °á°ú : 0 ÆäÀÌÁö: 8
  • ¿µ¹®
    ÇѱÛ
´ëÇѽŰæ¿Ü°úÇÐȸ ÀÇÇпë¾î »çÀü °Ë»ö ¸ÂÃã °Ë»ö °á°ú : 0 ÆäÀÌÁö: 8
  • ¿µ¹®
    ÇѱÛ
    ÇÑÀÚ
´ëÇѽŰæ¿Ü°úÇÐȸ ÀÇÇпë¾î »çÀü °Ë»ö À¯»ç °Ë»ö °á°ú : 0 ÆäÀÌÁö: 8
  • ¿µ¹®
    ÇѱÛ
    ÇÑÀÚ
´ëÇѱâ»ýÃæÇÐȸ ÀÇÇпë¾î »çÀü °Ë»ö ¸ÂÃã °Ë»ö °á°ú : 0 ÆäÀÌÁö: 8
  • ¿µ¹®
    ÇѱÛ
´ëÇѱâ»ýÃæÇÐȸ ÀÇÇпë¾î »çÀü °Ë»ö À¯»ç °Ë»ö °á°ú : 0 ÆäÀÌÁö: 8
  • ¿µ¹®
    ÇѱÛ
´ëÇÑ»ýÈ­ÇкÐÀÚ»ý¹°ÇÐȸ ¿ë¾î »çÀü °Ë»ö ¸ÂÃã °Ë»ö °á°ú : 0 ÆäÀÌÁö: 8
  • ¿µ¹®
    ÇѱÛ
KI ÀÇÇпë¾î »çÀü °Ë»ö ¸ÂÃã °Ë»ö °á°ú : 0 ÆäÀÌÁö: 8
  • ¿µ¹®
    ÇѱÛ
KI ÀÇÇпë¾î »çÀü °Ë»ö À¯»ç °Ë»ö °á°ú : 0 ÆäÀÌÁö: 8
  • ¿µ¹®
    ÇѱÛ
KMLE ÀÇÇоà¾î »çÀü ¸ÂÃã °Ë»ö °á°ú : 0 ÆäÀÌÁö: 8
KMLE ÀÚµ¿ÃßÃâ ÀÇÇоà¾î »çÀü ¸ÂÃã °Ë»ö °á°ú : 0 ÆäÀÌÁö: 8
ÀÇÇÐ³í¹® ¾àÀÚ(Pubmed/Entrez) °Ë»ö ¸ÂÃã °Ë»ö °á°ú : 0 ÆäÀÌÁö: 8
Çѱ¹Ç¥ÁØÁúº´»çÀκзù ¾àÀÚ ¸ÂÃã °Ë»ö °á°ú : 0 ÆäÀÌÁö: 8
  • ÄÚµå
    ¿µ¹®
    ÇѱÛ
Çѱ¹Ç¥ÁØÁúº´»çÀκзù ¾àÀÚ À¯»ç °Ë»ö °á°ú : 0 ÆäÀÌÁö: 8
  • ÄÚµå
    ¿µ¹®
    ÇѱÛ
°æºÏ´ë Ä¡°ú´ëÇÐ ±¸°­³»°ú ±³½Ç »çÀü ¸ÂÃã °Ë»ö °á°ú : 0 ÆäÀÌÁö: 8
  • ¿µ¹®
    ÇѱÛ
    ¼³¸í
CancerWEB ¿µ¿µ ÀÇÇлçÀü ¸ÂÃã °Ë»ö °á°ú : 0 ÆäÀÌÁö: 8
MeSH(Medical Subject Headings) ¸ÂÃã °Ë»ö (http://www.nlm.nih.gov) °á°ú : 0 ÆäÀÌÁö: 8
MeSH(Medical Subject Headings) À¯»ç °Ë»ö (http://www.nlm.nih.gov) °á°ú : 0 ÆäÀÌÁö: 8
¿ÜºÎ ¸µÅ© - Merriam-Webster's ÀÇÇлçÀü ¸ÂÃã °Ë»ö (https://www.merriam-webster.com) °á°ú: 0 ÆäÀÌÁö: 8
¿ÜºÎ ¸µÅ© - Merriam-Webster's ÀÇÇлçÀü À¯»ç °Ë»ö (https://www.merriam-webster.com) °á°ú: 0 ÆäÀÌÁö: 8
¿ÜºÎ ¸µÅ© - A.D.A.M. Medical Encyclopedia ¸ÂÃã °Ë»ö (http://www.nlm.nih.gov) °á°ú: 0 ÆäÀÌÁö: 8
¿ÜºÎ ¸µÅ© - A.D.A.M. Medical Encyclopedia À¯»ç °Ë»ö (http://www.nlm.nih.gov) °á°ú: 0 ÆäÀÌÁö: 8
¿ÜºÎ ¸µÅ© - MedlinePlus Health Topics ¸ÂÃã °Ë»ö (http://www.nlm.nih.gov) °á°ú: 0 ÆäÀÌÁö: 8
¿ÜºÎ ¸µÅ© - MedlinePlus Health Topics À¯»ç °Ë»ö (http://www.nlm.nih.gov) °á°ú: 0 ÆäÀÌÁö: 8
¿ÜºÎ ¸µÅ© - µå·¯±×ÀÎÆ÷ ¾àÇÐ Á¤º¸ ¸ÂÃã °Ë»ö (http://www.druginfo.co.kr) °á°ú: 0 ÆäÀÌÁö: 8
Á¦Ç°¸í
ÆÇ¸Å»ç
º¸ÇèÄÚµå ¼ººÐ/ÇÔ·®
±¸ºÐ/º¸Çè±Þ¿©
¿ÜºÎ ¸µÅ© - µå·¯±×ÀÎÆ÷ ¾àÇÐ Á¤º¸ À¯»ç °Ë»ö (http://www.druginfo.co.kr) °á°ú: 0 ÆäÀÌÁö: 8
Á¦Ç°¸í
ÆÇ¸Å»ç
º¸ÇèÄÚµå ¼ººÐ/ÇÔ·®
±¸ºÐ/º¸Çè±Þ¿©
¿ÜºÎ ¸µÅ© - WebMD.com Drug Reference ¸ÂÃã °Ë»ö (http://www.webmd.com) °á°ú: 0 ÆäÀÌÁö: 8
¿ÜºÎ ¸µÅ© - WebMD.com Drug Reference À¯»ç °Ë»ö (http://www.webmd.com) °á°ú: 0 ÆäÀÌÁö: 8
¿ÜºÎ ¸µÅ© - Drug.com Drugs by Medical Condition ¸ÂÃã °Ë»ö (http://www.drugs.com) °á°ú: 0 ÆäÀÌÁö: 8
¿ÜºÎ ¸µÅ© - Drug.com Drugs by Medical Condition À¯»ç °Ë»ö (http://www.drugs.com) °á°ú: 0 ÆäÀÌÁö: 8
KMLE À¥ ¿ë¾î ¸ÂÃã °Ë»ö °á°ú : 0 ÆäÀÌÁö: 8
KMLE À¥ ¿ë¾î À¯»ç °Ë»ö °á°ú : 0 ÆäÀÌÁö: 8
ÇÑ¿µ/¿µÇÑ »çÀü ¸ÂÃã °Ë»ö °á°ú : 0 ÆäÀÌÁö: 8
  • ¿µ¹®
    ÇѱÛ
ÇÑ¿µ/¿µÇÑ »çÀü À¯»ç °Ë»ö °á°ú : 0 ÆäÀÌÁö: 8
  • ¿µ¹®
    ÇѱÛ
WordNet ÀÏ¹Ý ¿µ¿µ »çÀü °Ë»ö °á°ú : 0 ÆäÀÌÁö: 8
¿ÜºÎ ¸µÅ© - American Heritage Dictionary ¿µ¿µ»çÀü ¸ÂÃã °Ë»ö (https://www.ahdictionary.com) °á°ú: 0 ÆäÀÌÁö: 8
¿ÜºÎ ¸µÅ© - American Heritage Dictionary ¿µ¿µ»çÀü À¯»ç °Ë»ö (https://www.ahdictionary.com) °á°ú: 0 ÆäÀÌÁö: 8
ÅëÇÕ°Ë»ö ¿Ï·á